Streetbeat News

Stock Prices

VVOS

Vivos Therapeutics has received FDA 510(k) clearance for its DNA appliance, designed to treat pediatric obstructive sleep apnea (OSA) and snoring. This approval allows Vivos to enter the pediatric market, potentially capturing significant market share. The device is non-invasive and effective, with clinical trials showing significant improvements in sleep-related symptoms. Vivos plans to quickly integrate this into its marketing model to scale revenue.

Portfolio Pulse from Vandana Singh

September 18, 2024 | 2:05 pm

AVGO

Broadcom (NASDAQ:AVGO) has significantly outperformed the market over the past 15 years, achieving an average annual return of 35.31%. A $100 investment in AVGO 15 years ago would be worth $9,384.48 today. This highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:01 pm

DDOG

Datadog (NASDAQ:DDOG) has significantly outperformed the market over the past 5 years, with an average annual return of 26.7%. A $100 investment in Datadog 5 years ago would now be worth $311.99, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:01 pm

MGNX

Macrogenics (NASDAQ:MGNX) has received mixed analyst ratings over the past three months, with a notable decrease in average price targets. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite challenges such as a decline in revenue and below-average financial metrics, Macrogenics maintains a strong market presence with its biotechnology focus.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:00 pm

WMB

Williams Companies (NYSE:WMB) has received diverse analyst ratings over the past three months, with a recent increase in the average 12-month price target to $46.0. Analysts have raised their ratings and price targets, reflecting a more positive outlook. Despite this, the company faces challenges with declining revenue growth and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:00 pm

PSEC

Prospect Capital's short interest has decreased by 6.79%, with 21.42 million shares sold short, representing 6.73% of its float. This is higher than its peers' average short interest of 3.52%. The decrease in short interest may indicate a shift towards a more bullish sentiment.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:00 pm

MGNI

In the past three months, 7 analysts have evaluated Magnite (NASDAQ:MGNI), with all ratings being bullish. The average 12-month price target increased by 6% to $19.43. Magnite, a major supply-side platform in online advertising, shows strong financial health with a notable revenue growth rate and efficient debt management.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:00 pm

NVVE

Nuvve Holding (NYSE:NVVE) has seen a significant decrease in its short percent of float, falling by 67.53% since the last report. Currently, 2.14% of its shares are sold short, which is higher than the peer group average of 1.68%. This decrease in short interest may indicate a shift in market sentiment towards a more bullish outlook.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:00 pm

UBS

UBS Gr's short interest has decreased by 11.9%, with 11.80 million shares sold short, representing 0.37% of its float. This is lower than its peers' average short interest of 2.25%. The decrease in short interest may indicate a more bullish sentiment towards UBS Gr.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:00 pm

SOUN

SoundHound AI (NASDAQ:SOUN) has been analyzed by six analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $7.17, with a high of $9.00 and a low of $6.00. Recent analyst actions include maintaining or raising ratings, reflecting positive sentiment. Despite strong revenue growth, SoundHound AI faces challenges with profitability and returns.

Portfolio Pulse from Benzinga Insights

September 18, 2024 | 2:00 pm